Rob Salmon

Dad and husband to my wonderful family. Former tech exec, NetApp, Cohesity. Golfer. Living w/ multiple myeloma. Patient advocate.

[Adam C Palmer @ac_palmer]

Sometimes cancer treatments are subject to hype, but here’s an advance that’s been understated:

Combining a T-cell engager antibody with daratumumab allowed >80% of people with relapsed or refractory multiple myeloma to go years without progression. Might be *permanent* control

[Samuel Hume @DrSamuelBHume]

How outcomes in relapsed/refractory multiple myeloma changed, from 1986 to 2026

[Doog @doogadoo11]

Damn.

I’m sure there’s a U.S. / Iran analogy in there somewhere.

[Vincent Rajkumar @VincentRK]

China has now surpassed all other countries in number of new oncology clinical trials launched each year, AND also number of novel active substances (NAS) for cancers launched. @IQVIA_global

https://t.co/hTOHIDdyo6

[Nathan Punwani @npunwani]

We’ve come a long way in multiple myeloma

#EBMT26

[Rob Salmon @salmon_rob]

Patty is running the Tokyo Marathon on March 1st. This marathon will complete the six majors in the world for Patty: Boston, Chicago, New York, Berlin, London, and Tokyo. How cool is that!

She is running for the Multiple Myeloma Research Foundation (MMRF). MMRF is a great organization focused on helping patients and caregivers on the myeloma journey. If you are so inclined, please visit Patty’s page and consider a donation to the MMRF. https://t.co/pZzQcgCgJ4 @MMRFTeam4Cures @theMMRF

[Jim Omel @IMFjimMYELOMA]

Gene Therapy-Induced CAR T Cells for Myeloma Could Alter Treatment Landscape https://t.co/bLzeYkE0sD Four patients with in-vivo induced CAR-T cell therapy.

[Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 @Rfonsi1]

It is time to change the nomenclature for MM treatment regimen acronyms. If it involves a Bispecific or CART, we need to add -Ig at the end to recognize the need for:

- Proactive
- Sufficient
- Ongoing until needed
- Closely monitored

IgG replacement.

Saying that an "x% of patients were replaced" is not enough. When? To what level? etc. It should never go under 400 mg/dL, and probably higher. We need to account for the M-spike concentration in IgG MM. With CART and bispecifics we are using regardless.
#ASH25RF #mmsm

[Rob Salmon @salmon_rob]

Hear the experts speak on the great progress made treating myeloma. If you care, this is one you don’t want to miss.

[International Myeloma Foundation @IMFmyeloma]

Join us at our free IMWG Conference Series webinar on December 17 when leading myeloma experts discuss the latest on myeloma research from the December 2025 American Society of Hematology Conference. Claim your spot now! >https://t.co/iqTAmkPapL

#mmsm #imfimwg #ASH25

[Rob Salmon @salmon_rob]

I appreciate the focus on infections as we see bispecific and car-t used more in front line. The possibility for less toxicity but more infections. A balancing act for sure but the impact on reducing myeloma burden is compelling.

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

#ASH25 the most important part of tec-dara beyond its outstanding efficacy in MajesTEC-3…

The combo can only be possible with appropriate infection prevention.

🚨 We now know - use primary IVIG prophylaxis with this and other BCMA bsAbs!

[Rob Salmon @salmon_rob]

Incredible results!

[Vincent Rajkumar @VincentRK]

Unprecedented. #ASH25

Tec-Dara in relapsed myeloma.
@mvmateos

[Rob Salmon @salmon_rob]

Game changers available in earlier lines of treatment leading to much longer PFS. This is just one of a few presented at #ASH25. @IMFmyeloma #IMFASH25

[Marc Braunstein, MD, PhD, FACP @docbraunstein]

Results of the MajesTEC-3 for #myeloma just published: https://t.co/c4wuBVITy3 Pending approval in earlier lines, this will change the paradigm of using bispecific antibodies in myeloma. #mmsm

[Rakesh Popat @DrRakeshPopat]

In-vivo BCMA CAR-T first in human trial. 3 patients all achieving MRD negativity.
This could be revolutionary - no need for lymphodepletion chemo, no complicated cell manufacturing process and better memory T cell phenotype.
Looking forward to more data esp safety
#ASH25

[Vincent Rajkumar @VincentRK]

Impressive. Bela-KPd in patients relapsing after CART in relapsed myeloma. #ASH25 @bdermanmd

-Lower dose of Belantamab every 8 weeks — this is critical.
-82% response rate
-Median PFS 15 months

[Teresa Miceli. ❤️&☮️4🌎 @IMFnurseMyeloma]

If you missed the Live action you can view the replay at https://t.co/9z7Z0lLdER
#ASH25 #mmsm @IMFMyeloma #IMFASH25

[Vincent Rajkumar @VincentRK]

630am
250+ myeloma docs
Standing room only, to the rafters. #ASH25

https://t.co/VFCSHjIiJ6
#IMWG #IMFASH25

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

#ASH25 #mmsm @ASH_hematology

Oral myeloma- long term CARTITUDE-4 in standard risk patients

@End_myeloma

✅ 80% progression-free & off treatment at 2.5 years
✅ 93% of 1-year responders remained progression-free at 2.5 years
✅ 100% of MRD-negative CR patients progression-free at 2.5 years
✅ No IEC-parkinsonism events, low non-relapse mortality

[Rob Salmon @salmon_rob]

The impact of Quads. #IMFAsh25 @IMFmyeloma

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

#ASH25 #mmsm @ASH_hematology

Treatment Refinement in Multiple Myeloma

@bdermanmd
Rates of MRD negativity with quad

[Rob Salmon @salmon_rob]

⁦@AlfredChung11⁩ kicking off the abstract presentations with an update on the Auriga trial. Dr. Chung is great to work with as a patient. I know, he is my doc. #ASH25 #IMFASH25 ⁦@IMFmyeloma⁩

[Rob Salmon @salmon_rob]

Humbling data. Much work to do.

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

#ASH25 #mmsm @ASH_hematology

Friday satellite program

Despite the emerging therapies in myeloma, many patients don’t access those therapies and maybe receiving sub-optimal therapy @SagarLonialMD